论文部分内容阅读
随着免疫检测点抑制剂类药物研究的深入,研究发现抗PD-1/PD-L1抑制剂仅在部分患者中获得良好的疗效,寻找可靠的生物标记以区别出可获益的人群是免疫治疗能否更好应用于临床的关键。抗PD-1/PD-L1免疫治疗的潜在预测标志物是从肿瘤细胞、免疫细胞以及各种细胞因子的生物学特性和彼此之间相互作用中寻找,目前研究最多的有PD-L2、TILs、IFN-γ、BIM、免疫评分、体细胞基因突变的负荷和MMR基因缺失等。全文就MMR基因缺失在结直肠癌抗PD-1/PD-L1免疫治疗疗效预测中作用作一综述。
With the development of inhibitors of immunodeficiency testing, it has been found that anti-PD-1 / PD-L1 inhibitors are effective only in some patients and finding reliable biomarkers to distinguish the beneficiaries from those who are immunized Whether the treatment can be better applied to the clinical key. Potential predictors of anti-PD-1 / PD-L1 immunotherapy are sought from the biological characteristics of tumor cells, immune cells, and various cytokines and their interactions with one another. Currently, the most studied of these are PD-L2, TILs , IFN-γ, BIM, immune score, load of somatic mutations and MMR gene deletion. The article reviews the role of MMR gene deletion in the prediction of the therapeutic effect of anti-PD-1 / PD-L1 immunotherapy in colorectal cancer.